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Abstract Liquid-chromatography (LC) high-resolution (HR)
mass spectrometry (MS) analysis can record HR full scans, a
technique of detection that shows comparable selectivity and
sensitivity to ion transitions (SRM) performed with triple-
quadrupole (TQ)-MS but that allows de facto determination
of “all” ions including drug metabolites. This could be of
potential utili ty in in vivo drug metabolism and
pharmacovigilance studies in order to have a more compre-
hensive insight in drug biotransformation profile differences
in patients. This simultaneous quantitative and qualitative
(Quan/Qual) approach has been tested with 20 patients chron-
ically treated with tamoxifen (TAM). The absolute quantifica-
tion of TAM and three metabolites in plasma was realized
using HR- and TQ-MS and compared. The same LC-HR-MS
analysis allowed the identification and relative quantification
of 37 additional TAM metabolites. A number of new metab-
olites were detected in patients’ plasma including metabolites
identified as didemethyl-trihydroxy-TAM-glucoside and
didemethyl-tetrahydroxy-TAM-glucoside conjugates corre-
sponding to TAMwith six and seven biotransformation steps,
respectively.Multivariate analysis allowed relevant patterns of
metabolites and ratios to be associated with TAM administra-
tion and CYP2D6 genotype. Two hydroxylated metabolites,
α-OH-TAM and 4′-OH-TAM, were newly identified as puta-
tive CYP2D6 substrates. The relative quantification was pre-
cise (<20 %), and the semiquantitative estimation suggests
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that metabolite levels are non-negligible. Metabolites could
play an important role in drug toxicity, but their impact on
drug-related side effects has been partially neglected due to
the tremendous effort needed with previous MS technologies.
Using present HR-MS, this situation should evolve with the
straightforward determination of drug metabolites, enlarging
the possibilities in studying inter- and intra-patients drug
metabolism variability and related effects.
Keywords Drugmetabolites . High-resolutionmass
spectrometry . Plasma . Quantification . Therapeutic drug
monitoring . Triple-quadrupole
Abbreviations
HR-MS High-resolution mass spectrometry
MDF Mass defect filtering
TDM Therapeutic drug monitoring
TQ-MS Triple-quadrupole mass spectrometer TDM
XIC Extracted ions chromatogram
Introduction
Adverse drug reactions (ADR) are a major concern as regards
the number of people exposed (millions), the number of
deaths (a few thousands), and financial costs (US$10–100
billion in a country such as the USA) [1–3]. Moreover, the
absolute number of ADR is steadily increasing due to (i) an
increased number of prescriptions, (ii) the increased number
of available drugs, and (iii) polymedication [2].
Recently, the importance of drug metabolites in ADR have
been specifically underscored with the release of Authority
Guidance for industry about the safety of drug metabolites
(Metabolites In Safety Testing (MIST) in 2008) and the Inter-
national Conference on Harmonization (ICH Guideline
M3(R2) in 2009/2010) [4, 5]. Today, drug developers must
address drug metabolite toxicology when their levels repre-
sent more than 10 % of the total drug-related exposure or if
they are present in disproportionate higher levels in humans
than in the tested animals [6].
The mechanisms of toxicity of a drug and its metabolites
are diverse and can be (i) on-target, (ii) off-target with the
binding of the drug/metabolites to an alternate target, or (iii)
related to the covalent binding of reactive metabolites to
proteins, nucleic acids, or membranes [7–9]. Strong side ef-
fects can also be observed with very low levels of metabolites
or at a very low frequency (<1 case in 1,000 patients). These
are rare events involving (alone or in combination) rare alleles
(single nucleotide polymorphisms (SNPs)), or drug–drug/–
herbal/–food interactions (induction and/or inhibition) able
to alter pharmacokinetics [10, 11]. Eventually, the realistic
safety profile of a new approved drug can only be appraised
after a number of years of public use [2]. This underscores the
huge significance of pharmacovigilance [12].
One main example of a drug whose metabolic pathways
and related pharmacodynamics has raised interest through the
last decades, is tamoxifen (TAM), a selective estrogen recep-
tor modulator, used for the prevention and adjuvant treatment
of estrogen-sensitive breast cancer. TAM is extensively me-
tabolized into active, inactive, and reactive metabolites though
different metabolic pathways involving different enzymes
(mainly cytochrome P-450 (CYP) and conjugation enzymes)
whose activities can vary intra- and inter-individually [7,
13–15]. Two metabolites, 4-hydroxy-TAM and endoxifen
(4-hydroxy-N-demethyl-TAM), show much higher activity
than the parent drug with up to 100-fold greater affinity
and potency in inhibiting estrogen receptors [13]. Patients
with lower endoxifen levels, as a consequence of the re-
duced CYP2D6 activity, are less likely to achieve benefit
from TAM treatment [14]. Conversely, patients with higher
endoxifen concentrations have higher frequency of side
effects. Other TAM metabolites could be related to the
occurrence of other ADR such as cancer via the formation
of reactive carbocation or benzoquinones [7]. Thus, the
extensive TAM biotransformation underscores the impor-
tance of comprehensive in vivo drug metabolism studies
[15–18].
In the present work, our objective was to show that now-
adays, the determination of a drug and tens of its metabolites
in human plasma is feasible with recent high-resolution mass
spectrometers (HR-MS; time-of-flight- and Orbitrap-MS). In
liquid-chromatography (LC) coupled to HR-MS analysis, the
detection of a drug and its metabolites can be performed by
high-resolution full scan (HR-FS) with comparable selectivity,
sensitivity, level accuracy, robustness, and ease of use to ion
transitions (SRM) performed with triple-quadrupole MS (TQ-
MS) [19–23]. This is why there is a replacement of TQ-MS by
HR-MS in many laboratories [24]. HR-FS acquisition records
virtually all ions and allows the determination of known or
unexpected compounds that can possibly be identified retro-
spectively. The selectivity of HR-FS takes place post-
acquisition by the construction of an extracted ion chromato-
gram (XIC) on the analyte theoretical m/z with a narrow mass
extraction window (MEW) [22].
As a noteworthy consequence for clinical pharmacologists,
HR-MS technology (i) offers the possibility to identify and
survey the exposure to a drug and tens of its metabolites and
(ii) allow, whenever needed, to extend drug monitoring to
many drug metabolites in patients’ samples, in order to relate
their concentrations with toxicity or efficacy. This is in line
with recent Authority’s demands about pharmacovigilance
[12, 25, 26].
In the present study, we have tested a quantitative and
qualitative (Quan/Qual) approach on 20 patients treated with
TAM. In parallel to the absolute quantification of TAM and
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three known metabolites by HR-MS and TQ-MS, the relative
quantification of 37 other identified TAM metabolites was
performed together with their provisional elucidation.
Materials and methods
Materials and reagents
(Z)-TAMwas purchased from Sigma-Aldrich (Germany). (Z)-
4-hydroxy-TAM (4-OH-TAM), (Z)-N-demethyl-TAM (N-
demethyl-TAM), N-demethyl-4-hydroxy-TAM 1:1 E/Z mix-
ture (N-demethyl-4-OH-TAM) and the deuterated internal
standards (IS): TAM-ethyl-D5 (TAM-IS), N-demethyl-TAM-
ethyl-D5 (N-demethyl-TAM/IS), 4-hydroxy-TAM-ethyl-D5
(4-OH-TAM/IS), and N-demethyl-4-hydroxy-TAM-ethyl-D5
(endoxifen-IS), were purchased from Toronto Research
Chemicals Inc. (Canada). Chromatography solvents and other
chemicals were of analytical grade (Merck (Darmstadt,
Germany).
Patients’ blood withdrawal, plasma extraction and CYP2D6
status
Blood samples were obtained from breast cancer patients
enrolled in a study protocol (ClinicalTrials.gov Identifier:
NCT00963209) approved by the local Ethics Committee
Patients received 20 mg TAM once or twice daily for
≥4 months. Blood samples were centrifuged (1,850×g,
10 min, +4 °C). Plasma were transferred and frozen at −20 °C.
As previously described in a method validated according to
FDA guidelines [27], the extraction was as follows: 100 μL of
plasma samples were mixed with 400 μL MeCN containing
the four IS (6.25 ng/mL). The mixture was centrifuged
(16,000×g, 10 min, 4 °C). Supernatants were transferred into
polypropylene tubes and evaporated at RT under a N2 flux.
The dried residues were reconstituted in 600 μL
MeOH/20 mM ammonium formate 1:1 (v/v) adjusted to pH
2.9 and re-centrifuged. Supernatants were transferred into
injection vials.
Patients were classified according to their CYP2D6 geno-
type as poor (PM; N=1), intermediate (IM; N=7), extensive
(EM; N=11), or ultra-rapid metabolizers (UM; N=1).
LC-MS methods and parameters
The analyses used two UHPLC systems coupled to a triple-
quadrupole Quantum Ultra MS (Thermo, USA) or an
Exactive Plus Orbitrap MS (Thermo, Germany) and included
a Rheos Allegro pump (Flux Instruments, Switzerland) and a
HTS PAL autosampler (CTC analytics, Switzerland) set at
10 °C. Heated electrospray ionization (H-ESI) was operated
in positive mode. All H-ESI and MS parameters were usual
values including spray voltage, 3.8–4.7 kV; sheath gas and
auxiliary nitrogen pressures, 40–60 and 10–20 respective
arbitrary units; declustering potential, 4–10 V; capillary tem-
perature, 300–350 °C; and tube lens voltages, 60 to 180 V.
The mobile phase was 10 mM ammonium formate+0.1 %
FA (A) and MeCN+0.1 % FA (B) and was delivered at
300 μL/min using the following stepwise gradient: T=
0 min, 20 % B; T=11 min maintained for 1.4 min, 55 % B;
T=12.5 min: initial conditions for 3.5 min. The analytical
column, 2.1×30 mm (i.d.×L) Acquity UPLC BEH C18
1.7 μm particle size (Waters, USA), was placed in an oven
set at +40 °C. The injection volume was 10 μL. Data acqui-
sition, peak integration, and quantification were performed
using Xcalibur software (Thermo, USA).
TQ-MS settings: quadrupole resolution, 0.7 U at FWHM;
collision gas (Arg) pressure, 1.5 mTorr, and transitions with
0.5 U and 0.02 s scan width and scan time, respectively. SRM
were recorded in centroid mode with the following precur-
sor→product m/z and collision-induced dissociation (see Ta-
ble 1 for abbreviations and chemical compositions). TAM,
372.3→72.1 at 23 eV; N-demethyl-TAM, 358.3→58.1 at
21 eV; 4-OH-TAM, 388.3→70.1+72.1+129.1 at 38/25/
25 eV; Endoxifen, 374.3→58.1+129.1+223.1 at 22/28/
20 eV; Endoxifen_IS, 377.3→72.1 at 24 eV; 4-OH-
TAM_IS:, 363.3→58.1 at 21 eV; N-demethyl-TAM_IS,
393.3→72.1 at 25 eV; and TAM_IS, 379.3→58.1 at 22 eV.
Exactive Plus-HR-MS settings: HR-FS alternating with
“all-ion fragmentation” MS (MSALL; high-energy collisional
dissociation=40 eV) scan: from m/z 200 to 800 and m/z 55 to
800, respectively. MSALL is the fragmentation of all precursor
ions entering the C-trap (no ion selections). C-trap capacity:,
106 charges; maximum injection time, 250 ms; and H-ESI
probe temperature, 300 °C. External mass calibration of the
Exactive Plus-MS was performed when mass accuracy was
less than or equal to ±4 ppm. Resolution, 70,000 and 17,500
FWHM for HR-FS and MSALL acquisition, respectively. XIC
were based on a ±5 ppm MEW.
LC-MS parameters for metabolite confirmation with MS2
acquisition
For confirmation and structure elucidation attempt of some
TAM metabolites, additional product scan acquisitions were
performed (MS2 with the precursor ion selection within a m/z
unit) on a Q-Exactive-MS (Thermo, Germany). UHPLC con-
ditions were similar to the analysis on the Exactive Plus-MS
but sample extracts were ten times more concentrated.
Quantitative analysis
As previously described [27], calibration curves were pre-
pared with TAM, 4-OH-TAM, N-demethyl-TAM, and
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and collected in K-EDTA Monovettes® (Sarstedt, Germany).
Table 1 List of compounds determined in this study. Compound identi-
fication number (ID no.), retention time (RT), monoisotopic m/z used to
construct extracted ion chromatograms (XIC), chemical composition,
abbreviated name, metabolite generation number (F), internal standrad
(IS no.) used for metabolite/IS ratio (relative quantification), determina-
tion coefficient (R2) between metabolite/IS and TAM/IS ratios and me-
tabolite mean peak area (AA) expressed in percent of TAM mean peak
area, are given
ID no. RT (min) m/z Chemical composition Identification name* F IS no. used R2◊ AA (% of TAM)
1 2.62 550.24354 C31H35NO8 Demethyl-TAM-O-Gluc_1 3 24 0.84 0.10 ●/◙
2 2.81 564.25919 C32H37NO8 TAM-OH-Gluc_1 2 24 0.69 0.06 ●/◙
3 3.44 578.23846 C32H35NO9 TAM-carboxy-Gluc 4 24 0.40 0.05 ◙
4 3.57 580.25411 C32H37NO9 DiOH-TAM-O-Gluc_1 4 24 0.82 0.13 ◙
5 3.64 570.23406 C30H35O10N Didemethyl-tetraOH-TAM-glucoside 7 24 0.67 0.03 ○
6 4.21 388.19072 C25H25NO3 Demethyl-TAM-COOH 4 24 0.57 0.17 ◙
7 4.36 406.23767 C26H31NO3 TAM-dihydrodiol 2 24 0.46 0.56 ●
8 4.43 402.20637 C26H27NO3 TAM-COOH 3 24 0.35 0.40 ◙
9 4.44 550.24354 C31H35NO8 Demethyl-TAM-OH-Gluc_2 3 24 0.35 0.05 ●/◙
10 4.54 374.21146 C25H27NO2 Demethyl-OH-TAM_1 2 24 0.93 0.36 ●/◙
11 4.59 564.25919 C32H37NO8 TAM-OH-Gluc_2 2 24 0.55 0.05 ●/◙
12 4.78 388.22711 C26H29NO2 α-OH-TAM 1 24 0.58 0.06 ●/◙
13 4.92 550.24354 C31H35NO8 Demethyl-TAM-OH-Gluc_3 3 24 0.43 0.14 ●/◙
14 4.97 418.20128 C26H27NO4 OH-TAM-COOH 4 24 0.57 0.21 ○
15 5.00 564.25919 C32H37NO8 TAM-OH-Gluc_3 2 24 0.58 0.15 ●/◙
16 5.35 404.22202 C26H29NO3 DiOH-TAM_1 2 24 0.68 0.26 ●/◙
17 5.57 404.22202 C26H29NO3 DiOH-TAM_2 2 24 0.72 0.40 ●/◙
18 5.80 564.25919 C32H37NO8 TAM-OH-Gluc_4 2 24 0.42 0.21 ●/◙
19 5.82 550.24354 C31H35NO8 Demethyl-TAM-OH-Gluc_4 3 24 0.38 0.08 ●/◙
20 5.90 468.18392 C26H29NO5S TAM-OH-sulfate 2 24 0.36 0.01 ●
21 5.92 580.25411 C32H37NO9 DiOH-TAM-O-Gluc_2 4 24 0.39 0.09 ◙
22 6.33 554.23846 C30H35O9N Didemethyl-triOH-TAM-glucoside_1 6 24 0.57 0.33 ○
23 7.05 360.19581 C24H25NO2 Didemethyl-OH-TAM 3 24 0.47 0.03 ◙
24 7.25 379.24284 C25H22D5NO2 Endoxifen_IS NA
25 7.27 374.21146 C25H27NO2 Endoxifen (Z-OH-demethyl-TAM_2) 2 24 0.31 4.05 ◙
26 7.29 554.23846 C30H35O9N Didemethyl-triOH-TAM-glucoside_2 6 28 0.74 0.04 ○
27 7.46 374.21146 C25H27NO2 OH-demethyl-TAM_3 2 28 0.49 0.23 ●/◙
28 7.50 393.25849 C26H24D5NO2 4-OH-TAM_IS NA
29 7.50 388.22711 C26H29NO2 4-OH-TAM 1 28 0.48 1.32 ●/◙
30 7.60 388.22711 C26H29NO2 3-OH-TAM 1 28 0.51 0.06 ●/◙
31 7.64 404.22202 C26H29NO3 DiOH-TAM_3 2 28 0.39 0.45 ●/◙
32 8.02 374.21146 C25H27NO2 Demethyl-OH-TAM_4 2 28 0.63 2.04 ●/◙
33 8.23 388.22711 C26H29NO2 4′-OH-TAM 1 28 0.79 1.85 ●/◙
34 9.60 372.23219 C26H29NO E-TAM ? 37 0.84 0.24 ○
35 9.69 344.20089 C24H25NO Didemethyl-TAM 2 37 0.84 5.50 ●/◙
36 9.69 356.20089 C25H25NO Demethyl-TAM-desat 2 37 0.85 0.36 ○
37 9.92 363.24792 C25H22D5NO N-demethyl-TAM_IS NA
38 9.95 358.21654 C25H27NO N-demethyl-TAM 1 37 0.90 118.80 ●/◙
39 9.95 370.21654 C26H27NO TAM-desat 1 40 0.97 0.31 ○
40 10.20 377.26357 C26H24D5NO TAM_IS NA
41 10.20 372.23219 C26H29NO TAM (parent drug) 0 40 1.00 100.0 ●/◙
42 10.43 386.21146 C26H27NO2 OH-TAM-desat_1 2 40 0.52 0.04 ○
43 10.70 388.22711 C26H29NO2 TAM-NO 1 40 0.60 4.83 ●/◙
44 11.77 374.21146 C25H27NO2 Demethyl-OH-TAM_5 2 40 0.65 0.38 ○
45 12.89 386.21146 C26H27NO2 OH-TAM-desat_2 2 40 0.44 0.07 ○
Abbreviations for metabolite identification: desat desaturated, OH hydroxylated, NO N-oxygenated, Gluc glucuronide, “white circles” never reported,
“black circles” reported in animals or incubations only, “inverse white circle” reported in human plasma
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Endoxifen (Z-isomers) at eight different levels ranging from
0.5 to 500, 0.2 to 200, 1 to 1,000, and 0.5 to 500 ng/mL
whereas quality control samples (QCs) were spiked at 3, 50,
375, and 1.2, 20, 150, and 6, 100, 750, and 3, 50, 375 ng/mL,
respectively. Patients’ plasma extracts were analyzed with the
LC-TQ-MS system and a few months later re-extracted and
analyzed with the LC-HR-MS system. Absolute quantifica-
tions were compared between the two analyses. Detection
sensitivity, robustness, and convenience were assessed.
Qualitative analysis (metabolite identification)
The exact same HR-MS data used for the absolute quantifica-
tion were reprocessed with Metworks 1.3 (Thermo, USA) for
metabolite identification (Qual analysis). MassFrontier 6.0
(Thermo, USA) was used for the structure elucidation with
the identification of fragment ions.
Two main strategies were employed for the identification
of TAM metabolites. First, XIC (MEW=5 ppm) around the-
oretical m/z values from 50 biotransformations predicted by
Metworks software 1.3 SP2, were constructed (see also pub-
lished list [28]). XIC of patients’ plasma extracts were com-
pared with blank plasma and calibrant extracts. Secondly, a
mass defect filtering (MDF) using Metworks software was
applied and all ions that did not enter the MDF limits were
removed. This MDF delimitation considered the mass defect
and nominalm/z values of TAMmetabolites discovered by the
first strategy and was defined as a square betweenm/z 0.165 at
m/z 250 (lower limits) andm/z 0.270 atm/z 600 (upper limits).
The MDF-cleaned spectra of a patient’s chromatogram were
checked visually scan by scan to reveal unexpected potential
TAM metabolites and their m/z constructs were compared in
patients’ and control plasma chromatograms.
For structure elucidation attempt of some identified TAM
metabolites, additional LC-MS analyses were performed with
a Q-Exactive HR-MS recording (true) MS2 product ion spec-
tra. Different collision energies were applied (see “Results”).
Semi- and relative quantification of TAM metabolites
After metabolite identification and confirmation, semi- and
relative quantifications of TAMmetabolites in the 20 patients’
plasma were assessed. Semiquantification is the estimation of
metabolite levels in universal units (e.g., ng/mL) but within a
large range (e.g., 0.1- to 10-fold accuracy) whereas relative
quantification is the more or less precise determination of
metabolites in arbitrary units.
With no pure standards of TAM metabolites, it is difficult
to evaluate accurately the absolute levels. Nevertheless,
semiquantification of TAM metabolites was estimated using
the following equation applied to mean values: TAM metab-
olite level (ng/mL)=((metabolite/TAM_IS peak area ratio) /
(TAM/TAM_IS peak area ratio))×TAM absolute level.
The relative quantification was done with LC peak area
ratios of TAM metabolites and IS. Metabolite/IS peak area
ratios were calculated to reduce variability. The IS selec-
tion for each TAM metabolite has been chosen based on
chemical structure similarities and retention times (see
Table 1).
Statistics and bioinformatics data treatment
Passing–Bablok regression (PB) and Bland–Altman test (BA)
have been used to assess the agreement between the two
analytical methods for the absolute quantification. Assump-
tions of linearity and normal distribution of differences, for
respectively PB and BA, have been assessed. For BA analysis,
due to the presence of proportional linear bias for some
analytes, mean difference (bias) between measurement and
limits of agreements were expressed as percentages of the
absolute analytes concentrations and percent difference plots
were used. Statistical analyses were performed using the
MedCalc software, version 12.7 (MedCalc Software, Ostend,
Belgium).
Multivariate analysis, including principal component anal-
ysis (PCA) and Partial Least Squares (PLS) regression, was
performed using SIMCA-P© v.13 (Umetrics, Sweden). PLS
aims at building a linear multivariate model by determining an
appropriate compromise between a synthetic description of
the variables and a good correlation with the response. A
leave-one-out cross-validation procedure was used to ensure
the robustness of the PLS model and its generalization ability.
For that purpose, the model was computed with data from 19
patients, leaving one subject out. The unseen sample was then
predicted by the model. The process was repeated 20 times,
once per subject. Model validity was further verified using
permutation tests and CV-ANOVA.
Results
Absolute Quantification of TAM and three metabolites
PB analysis performed on measured TAM levels, revealed the
presence of a linear proportional bias (see Electronic supple-
mentary material Fig. S1a and 1b). BA analysis shows the
estimated bias (expressed as % of mean absolute concentra-
tions of TQ and HR-MS) between the mehods and the lower
and upper limits of agreements (LOA) for TAM, N-demethyl-
TAM, 4-OH-TAM, and endoxifen levels, which were 5.6 %
(LOA, −12.3 and 25.5 %), −4.3 % (−25.4 and 10 %), −7.7 %
(−27.9 and 19.2 %), and −6 % (−27.9 and 19.2 %), respec-
tively (see Electronic supplementary material Fig. S1c).
Various minor differences in LC-MS conditions could
putatively explain the acceptable bias between the anal-
yses. Robust method-comparison experiment should be
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conducted under exact similar method conditions with
the same extracts and using a higher number of samples
in replicates.
The sensitivity of the two technologies was also compared.
The lowest levels detected were the first calibrants, 0.5, 0.2, 1,
and 0.5 ng/mL, with the TQ-MS, and 1, 0.8, 2, and 1 ng/mL
with the HR-MS for TAM, 4-OH-TAM, N-demethyl-TAM,
and endoxifen, respectively. Thus, in our analysis, the
Exactive Plus-HR-MS was two to four times less sensitive
than the TSQ-Ultra-TQ-MS. In both analyses, QCs and
calibrants accuracies were comparable. Calibration curves
recorded by the LC-HR-MS show a behavior similar to the
LC-TQ-MS.
In conclusion, our results confirm previous published data
[19–21] showing that LC-HR-MS is fully capable of
performing robust quantitative determinations in a productive
environment.
Identification of TAM metabolites
Using the software dedicated to drug metabolism and its
integrated list of predicted metabolites (m/z) to be extracted,
we rapidly identified most TAM metabolites by comparing
XIC from treated patients’ and control samples (Fig. 1). We
focused our comparison on two plasma samples showing the
highest TAM levels (344 and 446 ng/mL). Over a day, we
identified more than 40 potential TAM metabolites (LC
peaks). With MSALL acquisitions, we confirmed most of our
identifications by detecting TAM fragment ions that coeluted
with the metabolite precursor ion. The tolerance on mass
accuracy of the fragment ions was ±15 ppm (MSALL acquisi-
tion was set at a lower resolution=17,500). The fragmentation
of TAM in the HCD cell at 40 eV is presented in the Electronic
supplementary material Fig. S2a, b.
The most intense marker ion of TAM and its metabolites
was m/z=72.08078 corresponding to [C4H10N]
+ and was
found in most metabolite MSALL spectra. Using chromato-
grams and spectra cleaned by mass defect filtering, a few
additional ions were detected as potential metabolites whereas
they were not predicted. The last step of metabolite identifi-
cation, consisting in measuring the correlation between
TAM/IS and metabolite/IS LC peak area ratios, is given in
Table 1 (see examples in Fig. 2 for ID no. 7, 8, 22, 25, 38,
and 39). Metabolite candidates that were not correlated to
TAM/IS ratio (R2<0.1) were considered as false positives
and discarded. By contrast, a metabolite candidate with a R2
>0.25 was identified with additional evidence. The best
correlation was obtained with TAM-desat (ID no. 39; R2=
0.968), whereas the poorest value was observed with (Z)-
endoxifen (ID no. 25; R2=0.305) (Table 1; Fig. 2), a me-
tabolite whose formation is known to be controlled by
CYP2D6 activity.
Identification of TAM metabolites were considered as
“confirmed” only if the three following criteria were fulfilled:
(i) mass accuracy between measured and theoretical m/z<
±3 ppm; (ii) positive correlation (R2>0.1) between TAM
metabolite/IS and TAM/IS ratios; and (iii) presence of ≥2
fragment ions (MSALL or MS2 acquisition), with a mass
accuracy of less than ±15 ppm, identical to TAM or bearing
the metabolic change and coeluting with the precursor ion or
(iv) a fine isotopic distribution corresponding to the metabo-
lite chemical composition (e.g., 34S vs. 13C2).
Summarizing the results of the above investigations, Ta-
ble 1 shows all identified TAMmetabolites detected in plasma
extracts and present in at least eight patients (≥40 %). Simi-
larly, Fig. 1 shows the mean of 40 metabolite LC peak area
relatively to TAM mean area (in %) on a log-scale represen-
tation. Additional putative metabolites were detected (e.g.,
hydroxy-methoxy-TAM, demethyl-TAM-COOH and addi-
tional isomers of some metabolites depicted in Table 1) but
were below the detection limit in most patients (>12/20) with
our sample preparation and not considered further.
Examples of metabolite identification with the Exactive
Plus and Q-Exactive analyses are depicted in the Electronic
supplementary material Fig. S3a–e. MS2 spectra with frag-
ment ions and metabolite structure proposals of TAM-COOH
(ID no. 8), TAM-desat (ID no. 39), and TAM-dihydrodiol (ID
no. 7) as well as the fine isotopic distribution of OH-TAM-
sulfate at A+2 (m/zmonoisotopic+2 U=m/z 470; ID no. 20)
confirming the presence of a sulfur atom [29], are depicted.
In Fig. 3a, b, we describe the identification of three putative
glucose conjugates, namely two didemethyl-trihydroxy-
TAM-glucosides (ID no. 22 and 26) and one didemethyl-
tetraOH-TAM-glucoside (ID no. 5). These glucosides have
never been described and were revealed in MDF cleaned
spectra (see Electronic supplementary material Fig. S4a, b).
Key information to identify their chemical composition was
the capability to establish the absence of a sulfur atom using
the fine isotopic distribution (Fig. 3a). This information re-
duced significantly the chemical composition possibilities.
Taking metabolite no. 22 as a case in point, Fig. 3a challenges
two possible chemical compositions, with or without a sulfur
atom (which would derive from an initial glutathione conju-
gate): [C37H34ON2S]
+ and [C30H36O9N]
+. The theoretical
isotopic distribution of these two compositions is depicted
for A+2 (m/zmonoisotopic+2 U). A resolution of >75,000 is
sufficient to dissociate the two chemical compositions (m1
and m2) with a partial overlapping (resolution=1.5×[m1/
│(m1–m2)│]; see [22]). Figure 3b shows the fragmentation
pathways of one of the possible regioisomeric structures of
metabolite no. 22. Its fragmentation is very different from that
of TAM (see Electronic supplementary material Fig. S2a) due
to the proton location: on the tertiary amine for TAM and on
the glucosyl moiety for the glucoside. While neither their
positions of hydroxylation nor the point of attachment of the
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glucose moiety (on the –NH2 or an –OH group) could be
ascertained with the methodologies used, one can nevertheless
note that metabolites no. 22 and 26 correspond to six biotrans-
formation steps, whereas the more polar metabolite no. 5 (see
Electronic supplementary material Fig. S3a) corresponds to
seven steps.
To the best of our knowledge, many of the TAM metabo-
lites reported herein have never been detected before in pa-
tients’ plasma even if some were described in vitro or in
animals, e.g., TAM-dihydrodiol and TAM-OH-sulfate (see
ID no. 7 and in ID no. 20 in Table 1).
From our previous established retention time with pure
standards [27] and from literature [16, 18, 30], we have fully
identified eight metabolites, whereas in most cases absolute
configuration of identified TAM metabolites could not be
established (Table 1).
Other metabolites were never reported, namely: OH-TAM-
COOH (ID no. 14), N-demethyl-TAM-desat (ID no. 36),
TAM-desat (ID no. 39), OH-TAM-desat (ID no. 42, 45), and
the three glucosides (ID no. 5, 22, and 26). The characteriza-
tion of these new metabolites in patients’ plasma owes much
to the high sensitivity and selectivity of HR-FS and the ease to
trace potential metabolites with XIC constructions.
The four desaturated metabolites were identified from
their loss of m/z=2, most likely at the end of the –CH2CH3
side-chain, a CYP-catalyzed reaction energetically
favorable when the double bond so created is conjugated
with an aromatic system, as is the case here [31]. As for
glucosyl conjugates, they are seldom reported compared
with glucuronides, but their existence has been known
since decades [32, 33]. Their formation involves the cofac-
tor uridine-diphosphate glucose (UDP-glucose) and is cat-
alyzed by UDP-glucuronosyltransferases (UGTs) [34].
Glucosylation has been shown to occur at alcoholic, phe-
nolic and carboxylic –OH groups to yield O-glucosides and
at amido and amino groups to yield N-glucosides [32–36].
In our case, glucosylation could have occurred at one of the
hydroxy groups or at the primary amino group. It is also
remarkable that the glucosides were produced by six and
seven metabolic steps while remaining well above the de-
tection limit.
Semi- and relative quantification of TAM metabolites
The absolute quantification of 40 metabolites by LC-MS
analysis appears to be unrealistic and to a large extend useless.
However, a relative quantification of TAM metabolites (in
arbitrary units), if precise (less than ±30 %), can be used to
establish various associations between metabolite levels and
side-effects or treatment efficacy. Such associations are key
when one or a few metabolites are suspected to contribute to
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presented in Table 1. The mean absolute concentration of TAM was
208 ng/mL. The lowest metabolite (ID no. 20) represented 1/10,000 of
TAM peak area. Log-scale representation
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clinical events. This is the main goal of these metabolite
relative quantifications.
In LC-MS analysis, the detection intensity of a compound
is depending on its ionization yield and on the matrix effect at
its retention time, both depending on sample cleanup and LC-
MS. Using constant extraction procedure and LC-MS param-
eters, the ionization yield can be considered as similar be-
tween samples especially when weighted by internal
standards.
Matrix effect was evaluated in our method with
postcolumn infusion of TAM, 4-OH-TAM, N-demethyl-
TAM, and endoxifen [27]. Water and different plasma extracts
showed a low difference and low variability of matrix effects
for TAM, 4-OH-TAM, and endoxifen with less than or equal
to ±20 % during the entire chromatogram (1 to 13 min). When
IS were permuted in our relative quantifications (e.g.,
metaboliteID no. 7/ISID no. 24 vs. metaboliteID no. 7/ISID no. 40,
etc.), no significant impact on relative quantification was
observed (40 linear regressions gave determination coeffi-
cients (R2)≥0.977; mean=0.990±0.005; see typical correla-
tions in Electronic supplementary material Fig. S5a). The
precision of the relative quantification (determined area ratios
vs. predicted ratios from the correlations; N=380), remains
between 85 and 117 %. Previous results [37] obtained with
similar sample preparation and LC conditions showed low
impact of matrix effects on relative quantification. Taking into
account the precision (less than ±20 %) of our relative deter-
mination of TAM metabolites, data were processed further.
Relations between relative levels of TAM metabolites and
TAM (TAM metabolite/IS against TAM/IS peak area ratios)
for each metabolite gave various information. Indeed, R2
values decreased with the number of biotransformation steps
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(= metabolite generation, F, see Fig. 4a), indicating increased
inter-patient variability in metabolite production with the im-
plication of additional metabolizing enzymes. The decrease of
R2 values was less pronounced when considering F1–F4
(linear equation; slope=−0.057) rather than F1–F2 or F1–F3
(slope=−0.105 and −0.111, respectively). This decrease was
almost abolished when all metabolite generations, F1 to F7,
were taken into account (linear equation; slope=−0.007;
Fig. 4a). This observation could be explained by the fact that
F4–F7 metabolites were produced by the same enzymes than
the F1, F2, and F3 metabolites, and/or that F4–F6 metabolites
were produced from previous metabolite generations in a sort
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Fig. 3 Identification of TAM glucose conjugate metabolites measured at
m/z 554.23888. (a) Two possible chemical compositions, [C37H34ON2S]
+
and [C30H36O9N]
+, show mass accuracy (MA)=+0.4 and +0.8 ppm,
respectively. The chemical composition was elucidated with the fine
isotopic distribution of (A+2) corresponding to the theoretical distribu-
tions depicted as Proposals 1 and 2. The minimum resolution (Rmin) to
resolve completely [C37H34ON2
34S]+ and [C35
13C2H34ON2S]
+ or
[C28
13C2H36O9N]
+ or [C30H36O8
18ON]+ is 100,000 and 450,000, respec-
tively. Bottom, (A+2) spectrum. HR-MS resolution were set up at 140,000
(at m/z=200) that corresponds to 85,000 at m/z 556 (measured resolu-
tion). This is sufficient to conclude to the absence of a sulfur atom in this
chemical composition. The insert (bottom right) shows them/zmonoisotopic,
A, A+1, and A+2 of this metabolite measured in full-scan spectra. The
measured and theoretical relative isotopic abundance (RIA) values are
given. (b) One of the possible regioisomers (hydroxylation and glucose
attachment sites) corresponding to the composition C30H36O9N and to the
proposed fragmentation pathway from HR-MS2 product scan. Abbrevi-
ations: i inductive cleavage, Lib fragmentation predicted using a library
reaction, π ionization on pi bonds, rHB charge site rearrangement (α,β),
rHC charge site rearrangement (γ), rHR charge remote rearrangement.
Additional information is given in the Electronic supplementary material
S4a–c (see text)
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of production line of various metabolizing enzymes associated
on the endoplasmic reticulum membrane. When the relative
concentrations of TAM metabolites, expressed in percent of
TAM levels ((TAM metabolite/IS mean peak area ratios) /
(TAM/IS mean peak area ratios)), were plotted against metab-
olite generation, they decreased from F1 to F3 but remained
constant from F3 to F4 (Fig. 4b).
In a global perspective, Fig. 4a, b underscores the
importance to study in vivo drug metabolism and ther-
apeutic monitoring beyond the usual first- or second-
generation metabolites, as the formation to toxic/reactive
metabolites is by far not restricted to the first metabolic
steps [17].
Without pure standards, the semiquantitative estimation of
drug metabolites can be realized by comparing UV and MS
signals [6]. This can be difficult when small amounts of
metabolites prevent good UV detection, or when biotransfor-
mation strongly modifies UV absorbance. In this study, we
have estimated the absolute level of TAM metabolites based
on peak areas and TAM absolute mean level (see “Materials
and methods” for the equation). In the Electronic supplemen-
tary material Fig. S5b, eight metabolite levels were given in
percent of TAM absolute levels (this work and [30]) or in
percent of TAM peak area. The maximum difference between
these two calculations was observed with didemethyl-TAM
(ID no. 35). In this case, didemethyl-TAM mean level was 5-
fold underestimated when considering the relative quantifica-
tion rather than the absolute levels. This is due to a lower
attraction of H+ for the primary amino group (didemethyl-
TAM) compared with the tertiary amino group (TAM) and a
lower ionization yield. The absolute levels of the seven other
metabolites were only slightly underestimated by their peak
area: mean=−40 % (from −80 to −10 %) (see Electronic
supplementary material Fig. S5b). As most new metabolites
detected in our samples show peak area between 0.1 and 1 %
of TAM peak area (Fig. 1; Table 1), we can estimate that these
metabolites are probably in the range of 0.2 to 2 ng/mL of
plasma (corresponding to 0.1–1 % of TAM absolute mean
level in this study). According to the blood concentrations of
known toxic compounds listed by the International
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Association of Forensic Toxicologists (http://www.tiaft.org/)
[38, 39], the TAMmetabolite levels estimated in this work are
comparable to those of many compounds that show toxicity at
very low concentrations (clenbuterol, digoxin, fentanyl, etc.).
Such a comparison underscores that drug metabolites, even at
low levels, can have an impact on human body homeostasis
and that, when needed, clinical investigations should associate
plasma metabolite concentrations with drug toxicity or
efficacy.
Statistics and bioinformatics data treatment
Multivariate analysis was performed to provide an overall
picture of the drug metabolism events occurring after TAM
administration, by accounting for all the information provided
by the 40 measured metabolites. In order to highlight charac-
teristic metabolic patterns related to TAM plasma values, the
TAM relative concentration was used as a response vector to
be predicted as a linear combination of its metabolites using a
PLS regression model. A PLS model with three latent vari-
ables fitted the dataset well, as shown by the high R2 value
(R2=0.97), and was selected as the optimal model size ac-
cording to prediction ability evaluated by leave-on-out cross-
validation (Q2=0.92, CV-ANOVA; p<0.01). The distribution
of the samples on the PLS score plot revealed a clear separa-
tion of the patients on the first latent variable according to the
TAM dose administered, i.e., patients with a single (20 mg) or
double daily dose (40 mg; data not shown). This underlines
the strong effect of the dose on the measured metabolites
relative concentrations (see also the correlation coefficients
in Table 1). This influence was confirmed by the loadings
examination, as all metabolite concentrations were increased
for patients receiving a double dose compared with the single
dose group (data not shown). The observed vs. predicted plot
(Fig. 5a) highlighted a clear trend caused by the TAM dose but
additional inter-individual variabilities resulted in a well-
balanced continuous distribution of TAM plasma values.
The Variables Importance in Projection (VIP) scores were
0.01
0.10
1.00
10.00
100.00
0 1 2 3 4 5 6 7
TA
M
 m
et
ab
ol
ite
s 
in
 %
 
o
f
TA
M
 in
 re
la
tiv
e 
le
ve
ls
Number of biotransformation steps
(metabolite generation, F)
0.00
0.20
0.40
0.60
0.80
1.00
0 1 2 3 4 5 6 7
F1-2 : y = - 0.105x + 0.794
F1-3 : y = - 0.111x + 0.803
F1-4 : y = - 0.057x + 0.708
F1-7 : y = - 0.007x + 0.613
1
3
4
1
3
4
R
2
be
tw
ee
n
 T
AM
 m
et
ab
ol
ite
s 
an
d 
TA
M
 in
 re
la
tiv
e 
le
ve
ls
Number of biotransformation steps
(metabolite generation, F)
2
2
TAM
a
b
6 19 6 5 0 2 1
N-demethyl-TAM
Z-Endoxifen
N =
Fig. 4 (a) Determination
coefficient (R2) between relative
levels of TAM metabolites and
TAM (TAM metabolite/IS vs.
TAM/IS peak area ratios; see
Fig. 2) against metabolite
generation (F). Each diamond
represents the R2 value for a given
metabolite. Trend line equations
taking into account different F are
depicted. (b) TAM metabolite
relative levels for each metabolite
(TAM metabolite/IS peak area
mean in percent of and TAM/IS
peak area mean) vs. metabolite
generation, F. Log-scale
representation. The number of
TAM metabolites per generation
is shown in the boxes beneath the
plot. Open and filled diamonds
stand for phases I and II
metabolites, respectively. (E)-
Tam is not depicted because it
could be produced by chemical or
enzymatic isomerization (F0 or
F1, respectively)
Global monitoring of tamoxifen and its metabolites in human plasma 2637
then investigated to highlight characteristic metabolites
related to the TAM level response. A VIP score greater
than 1 indicates a potentially important variable in the
model considered. As shown in Fig. 5b, the highest VIP
scores were obtained for TAM_desaturated (1.31), OH-
demethyl-TAM_1 (1.27), and N-demethyl-TAM (1.25).
Therefore, the most characteristic metabolites of the
TAM plasma concentrations could be highlighted (see also
R2 values in Table 1).
To circumvent the major source of variability related to the
dose when investigating the whole set of measured metabo-
lites, a subset of 32 metabolites ratios was selected based on
possible sequential biotransformation. This biologically driv-
en selection aimed at uncovering metabolic patterns associat-
ed with CYP2D6 enzymatic activity. Thus, a PCA model was
then computed to assess patients’ groupings with respect to
their CYP2D6 genotypes. A trend separating poor, intermedi-
ate, extensive and ultra metabolizers is depicted on the first
d Substrate metabolite ratios PC1 Loading
N-demethyl-TAM Z-Endoxifen 0.301
4'-OH-TAM TAM-dihydrodiol 0.296
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principal component, as presented on Fig. 5c. Even if princi-
pal components correspond to directions maximizing the var-
iance without any objective of class separation, the selection
of biologically relevant metabolic ratios allowed the effects of
the CYP2D6 genotypic diversity to be highlighted as the
major source of variability in the reduced dataset (30.3 % of
the initial variance). Metabolites ratios were then associated
with either poor/intermediate or extensive/ultra genotypes
according to their position on the loading plot (data not
shown). Interestingly, the 12 most distinctive ratio character-
izing extensive and ultra metabolizers were related to 4 com-
pounds, namely TAM, N-demethyl-TAM, α-OH-TAM, and
4′-OH-TAM (Fig. 5d). While the two first are known
CYP2D6 substrates, these results suggest that α-OH-TAM
and 4′-OH-TAM may also be biotransformed in vivo by
CYP2D6. This example with TAM metabolism shows that
extended drug-metabolite profiling could be applied to most
drug deserving similar investigations (e.g., when a metabolite-
related ADR is suspected).
Discussion and perspectives
The advantage of HR-MS allowed us to study in greater depth
and with better convenience TAM metabolites in patients in
parallel with the quantification of TAM and its metabolites.
Such a Quan/Qual analysis could be of potential utility in
in vivo drug metabolism and pharmacovigilance studies in
order to reach broader insights in inter-patient drug biotrans-
formation profile and relate metabolite concentrations with
toxicity.
Some metabolites were detected for the first time in pa-
tients’ plasma whereas others had never been described be-
fore. Thus, putative didemethyl-trihydroxy- and didemethyl-
tetrahydroxy-TAM-glucoside conjugates were identified, im-
plying six and seven biotransformation steps, respectively. It
is noteworthy to mention that glucosides are seldom reported
in the literature compared with glucuronides. This finding
underscores the potential need to determine metabolites
formed by more than the usual one, two or three biotransfor-
mation steps in subpopulation showing specific events. The
overview of TAM biotransformations found in this study is
depicted in Fig. 6.
Metabolites are known to play an important role in drug
toxicity, particularly chemically reactive ones, but the assess-
ment of their impact in drug-related side effects has been
somewhat neglected due to the considerable time and effort
needed with previous MS technologies. Using the latest HR-
MS techniques, this situation should evolve and allow an
easier access to the production of late-generation metabolites
with a view to reaching a more comprehensive understanding
of the relation between metabolites and adverse effects in
patients with particular genetic traits, life style, and environ-
mental exposure.
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